- January 12, 2021
- Posted by: Bastion team
- Category: Markets
This post was originally published on this site
(RTTNews) – Vir Biotechnology, Inc. (VIR) and GlaxoSmithKline plc (GSK, GSK.L) announced Tuesday an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial.
The trial is due to begin in the first quarter of 2021.
VIR-7832 is a neutralizing COVID-19 antibody…
Recommended articles
- Elon Musk says Tesla has held 'preliminary discussions' to license its Autopilot software to other manufacturers
BRENDAN SMIALOWSKI/AFP via Getty ImagesElon Musk said Tesla has held early talks to license its software with other car manufacturers. The CEO has said in the past he is not looking to edge out other...(read more)
- Uravan Anounces the Sale of Fathom Shares
CALGARY, AB, Jan. 27, 2021 /CNW/ - Uravan Minerals Inc. (TSXV: UVN) ("Uravan") announces the sale of Uravan's 2,500,000 common shares of Fathom Minerals Ltd.("Fathom"), a private corporation, priced a...(read more)
- Levi's sales are down as remote workers turn to loungewear over jeans
Joe Raedle/Getty ImagesLevi's revenue in the recent holiday quarter was down 12% year-over-year. Sales beat expectations as losses slowed in the fourth quarter. As many remote workers trade out their...(read more)
- New Zealand Has NZ$17 Million Trade Surplus
(RTTNews) - New Zealand had a merchandise trade surplus of NZ$17 million in December, Statistics New Zealand said on Thursday - following the NZ$252 million surplus in November. Exports fell NZ$149 mi...(read more)
Bastion Balance Seoul, Korea.
